Lytix Biopharma AS (STU:6BG) Valuation Rank

View and export this data going back to 2021. Start your Free Trial

What is Lytix Biopharma AS Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Lytix Biopharma AS Valuation Rank Related Terms

Thank you for viewing the detailed overview of Lytix Biopharma AS's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lytix Biopharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lytix Biopharma AS (STU:6BG) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

LYTIX:Norway

Address

Sandakerveien 138, Oslo, NOR, 0484

Website

https://www.lytixbiopharma.com

Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401, and LTX-315 are in the pipeline.